false 0001211583 0001211583 2025-06-03 2025-06-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

Form 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 3, 2025

 

FENNEC PHARMACEUTICALS INC.

 

(Exact name of registrant as specified in its charter)

 

001-32295

(Commission File Number)

 

British Columbia, Canada   20-0442384

(State or other jurisdiction of

incorporation)

   (I.R.S. Employer Identification No.)

 

PO Box 13628, 68 TW Alexander Drive,

Research Triangle Park, NC

  

 

27709

(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (919) 636-4530

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Title of each class Trading symbol(s) Name of each exchange on which 
registered
Common FENC, FRX Nasdaq, TSX

 

 

 

 

 

Item 5.07Submission of Matters to a Vote of Security Holders.

 

On June 3, 2025, Fennec Pharmaceuticals Inc. (the “Company”) held an annual meeting of shareholders (the “Meeting”). The shareholders approved all proposals considered at the Meeting and approved all nominees of the Company for director, as follows:

 

1.                   The following five (6) nominees were elected to serve as directors, each to serve until the next annual meeting of shareholders of the Company or until their respective successor shall have been duly elected or duly approved:

 

Name of Nominee Votes For Votes Withheld Broker Non-Votes
Dr. Khalid Islam 13,432,561 304,760 5,580,283
Chris A. Rallis 13,808,792 354,099 5,580,283
Marco Brughera 13,807,501 355,390 5,580,283
Jodi Cook 13,259,894 902,997 5,580,283
Rostislav Raykov 13,432,561 730,330 5,580,283
Jeffrey Hackman 13,495,309 687,582 5,580,283

 

2.                   The resolution to appoint Haskell & White LLP as independent public accounting firm of the Company and to authorize the Board of Directors to fix their remuneration was approved based on the following vote:

 

Votes For 19,673,487
Votes Withheld 69,405
Votes Against 282
Broker Non-Votes 0

 

3.                   The resolution to vote on the advisory vote on executive compensation was approved based on the following vote:

 

Votes For 12,110,598
Votes Against 1,595,423
Abstentions 456,870
Broker Non-Votes 5,580,283

 

4.                   The resolution to vote on the proposed amendment to the 2020 Equity Incentive Plan was approved based on the following vote:

 

Votes For 12,927,131
Votes Against 776,907
Abstentions 458,853
Broker Non-Votes 5,580,283

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    FENNEC PHARMACEUTICALS INC.
     
Date June 3, 2025 By: /s/ Robert Andrade
   

  Robert Andrade

  Chief Financial Officer

 

3

 

v3.25.1
Cover
Jun. 03, 2025
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 03, 2025
Entity File Number 001-32295
Entity Registrant Name FENNEC PHARMACEUTICALS INC.
Entity Central Index Key 0001211583
Entity Tax Identification Number 20-0442384
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One PO Box 13628
Entity Address, Address Line Two 68 TW Alexander Drive
Entity Address, City or Town Research Triangle Park
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27709
City Area Code 919
Local Phone Number 636-4530
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common
Trading Symbol FENC
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Fennec Pharmaceuticals (NASDAQ:FENC)
Historical Stock Chart
From Jun 2025 to Jul 2025 Click Here for more Fennec Pharmaceuticals Charts.
Fennec Pharmaceuticals (NASDAQ:FENC)
Historical Stock Chart
From Jul 2024 to Jul 2025 Click Here for more Fennec Pharmaceuticals Charts.